Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.
Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK, Deane AM, Ostermann M, Wunderink RG, Boldt DW, Kroll S, Greenfeld CR, Hodges T, Chow JH; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Wieruszewski PM, et al. Among authors: wunderink rg. Crit Care. 2023 May 5;27(1):175. doi: 10.1186/s13054-023-04446-1. Crit Care. 2023. PMID: 37147690 Free PMC article. Clinical Trial.
Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension.
National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network; Shapiro NI, Douglas IS, Brower RG, Brown SM, Exline MC, Ginde AA, Gong MN, Grissom CK, Hayden D, Hough CL, Huang W, Iwashyna TJ, Jones AE, Khan A, Lai P, Liu KD, Miller CD, Oldmixon K, Park PK, Rice TW, Ringwood N, Semler MW, Steingrub JS, Talmor D, Thompson BT, Yealy DM, Self WH. National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network, et al. N Engl J Med. 2023 Feb 9;388(6):499-510. doi: 10.1056/NEJMoa2212663. Epub 2023 Jan 21. N Engl J Med. 2023. PMID: 36688507 Free PMC article. Clinical Trial.
Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study.
Hoste E, Bihorac A, Al-Khafaji A, Ortega LM, Ostermann M, Haase M, Zacharowski K, Wunderink R, Heung M, Lissauer M, Self WH, Koyner JL, Honore PM, Prowle JR, Joannidis M, Forni LG, Kampf JP, McPherson P, Kellum JA, Chawla LS; RUBY Investigators. Hoste E, et al. Intensive Care Med. 2020 May;46(5):943-953. doi: 10.1007/s00134-019-05919-0. Epub 2020 Feb 6. Intensive Care Med. 2020. PMID: 32025755 Free PMC article.
Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.
Alipanah-Lechner N, Hurst-Hopf J, Delucchi K, Swigart L, Willmore A, LaCombe B, Dewar R, Lane HC, Lallemand P, Liu KD, Esserman L, Matthay MA, Calfee CS; I-SPY COVID Consortium. Alipanah-Lechner N, et al. Crit Care. 2024 Feb 21;28(1):56. doi: 10.1186/s13054-024-04819-0. Crit Care. 2024. PMID: 38383504 Free PMC article. Clinical Trial.
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
Martin-Loeches I, Shorr AF, Wunderink RG, Kollef MH, Timsit JF, Yu B, Huntington JA, Jensen E, Bruno CJ. Martin-Loeches I, et al. Among authors: wunderink rg. Ann Intensive Care. 2023 Feb 11;13(1):8. doi: 10.1186/s13613-022-01084-8. Ann Intensive Care. 2023. PMID: 36773112 Free PMC article.
An Adjudication Protocol for Severe Pneumonia.
Pickens CI, Gao CA, Bodner J, Walter JM, Kruser JM, Donnelly HK, Donayre A, Clepp K, Borkowski N, Wunderink RG, Singer BD; NU SCRIPT Study Investigators. Pickens CI, et al. Among authors: wunderink rg. Open Forum Infect Dis. 2023 Jul 1;10(7):ofad336. doi: 10.1093/ofid/ofad336. eCollection 2023 Jul. Open Forum Infect Dis. 2023. PMID: 37520413 Free PMC article.
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D. Kaye KS, et al. Among authors: wunderink rg. Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11. Lancet Infect Dis. 2023. PMID: 37182534 Clinical Trial.
Machine learning links unresolving secondary pneumonia to mortality in patients with severe pneumonia, including COVID-19.
Gao CA, Markov NS, Stoeger T, Pawlowski A, Kang M, Nannapaneni P, Grant RA, Pickens C, Walter JM, Kruser JM, Rasmussen L, Schneider D, Starren J, Donnelly HK, Donayre A, Luo Y, Budinger GRS, Wunderink RG, Misharin AV, Singer BD; NU SCRIPT Study Investigators. Gao CA, et al. Among authors: wunderink rg. J Clin Invest. 2023 Jun 15;133(12):e170682. doi: 10.1172/JCI170682. J Clin Invest. 2023. PMID: 37104035 Free PMC article.
348 results